SLC6A3 and Parkinson disease: Across different series, subclinical loss of putamen 18F-dopa uptake or DAT binding can be detected in a majority of RBD cases suggesting they could provide a suitable population for trialing the protective efficacy of putative neuroprotective agents for PD.